TMO
$629.27+0.27%Real quote · delayedLife science tools🏛️ Company factsSEC filings + FINRA official data
Annual revenue $44.6B · latest quarter up 10.5% YoY · profitable (FY net income $6.7B) · short activity within its normal range.
FY revenue
$44.6B
2025-12
Latest Q YoY
+10.5%
Gross margin
11.9%
FY net income
$6.7B
Diluted EPS
$17.77
Short volume
45.2%
20d avg 45.4% · normal
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-04-30passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-27passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability High · 76/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$6.03 vs $5.71+5.6%
- Mar 2026$5.44 vs $5.20+4.62%
- Dec 2025$6.57 vs $6.43+2.18%
- Sep 2025$5.79 vs $5.50+5.27%
This company habitually beats by +4.4% — the next report has to clear that bar to count as good news. Analysts raised estimates 4× in 4 weeks — the bar is rising too. Analysts cut estimates 3× in 4 weeks.
Analyst estimates, not our forecast · not investment advice
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · dot = engine's call · color = outcome, arrow = direction
📜 Call history (newest first
3 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →